Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on December 21, 2004. The filing discloses a material definitive agreement entered into on the same date regarding executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate action rather than periodic financial performance.
Material Changes
On December 21, 2004, the Compensation Committee of the Board of Directors granted a stock option to John M. Maraganore, Ph.D., the President and Chief Executive Officer. The key terms of this agreement are:
- Option Size: Up to 250,000 shares of common stock.
- Exercise Price: $7.47 per share.
- Plan: Granted under the 2004 Stock Incentive Plan.
- Vesting Condition: The option vests upon the attainment of a corporate goal. The Compensation Committee retains discretion to determine if the goal is met and the specific number of shares that vest.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed beyond the standard disclosure of the option agreement terms.
Investor Verification Checklist
- Verify the specific "corporate goal" defined by the Compensation Committee that triggers vesting for the 250,000 shares.
- Confirm the total number of shares authorized under the 2004 Stock Incentive Plan and the remaining availability after this grant.
- Review the full text of the Nonstatutory Stock Option Agreement (Exhibit 10.1) for additional vesting schedules or forfeiture conditions.